Doctor profile · Federal record
Dr. MARK LEHMAN, MD
Dermatology Physician (CMS: DERMATOLOGY) · TULSA, OK
- NPI 1932195815
- Accepts Medicare
- MIPS 100.0 / 100 · 2023
- 34 yrs in practice
- Male
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
2121 E 21ST ST
TULSA, OK 741141409
(918) 749-2261
fax (918) 749-8712 - Mailing address
-
PO BOX 52588
TULSA, OK 741520588
Credentials & registration
- NPI registered
- September 2005 — 21 yrs on file
- Profile last updated
- May 16, 2008
- Year of graduation
- 1992 — 34 yrs since
- Specialty taxonomy
- 207N00000X — NUCC code
- State license (1)
- Oklahoma #19733
- Medicaid
- OK #100157070A
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1932195815. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
9,539
Distinct HCPCS
10
Medicare allowed
$508,683
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
17003 |
Destruction of precancer skin growth, 2-14 growths | 3,815 | 648 | $6 | |
99213 |
Established patient office or other outpatient visit, 20-29 minutes | 2,111 | 1,208 | $85 | |
17000 |
Destruction of precancer skin growth, 1 growth | 1,407 | 863 | $50 | |
17110 |
Destruction of skin growth, 1-14 growths | 665 | 481 | $101 | |
99214 |
Established patient office or other outpatient visit, 30-39 minutes | 504 | 363 | $121 | |
11102 |
Biopsy of related skin growth, first growth | 270 | 234 | $84 | |
99203 |
New patient office or other outpatient visit, 30-44 minutes | 110 | 110 | $105 | |
99212 |
Established patient office or other outpatient visit, 10-19 minutes | 88 | 86 | $53 | |
17004 |
Destruction of precancer skin growth, 15 or more growths | 78 | 51 | $157 | |
17262 |
Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 61 | 53 | $155 |
In context: peer comparison
Among 10 peers in this city , average services per provider: 240. This provider delivers 40× the peer median.Open Payments
Industry payments received
All-time total
$3,065
Transactions
148
Manufacturers
15
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| ABBVIE INC. | 27 | $600.74 | |
| Regeneron Healthcare Solutions, Inc. | 10 | $241.14 | |
| E.R. Squibb & Sons, L.L.C. | 14 | $229.79 | |
| Janssen Biotech, Inc. | 13 | $214.37 | |
| Novartis Pharmaceuticals Corporation | 12 | $212.18 | |
| Amgen Inc. | 7 | $191.66 | |
| Lilly USA, LLC | 12 | $182.87 | |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 8 | $171.60 | |
| Arcutis Biotherapeutics, Inc. | 14 | $163.48 | |
| Incyte Corporation | 11 | $155.12 | |
| Dermavant Sciences, Inc. | 7 | $119.37 | |
| UCB, Inc. | 1 | $111.91 | |
| Ortho Dermatologics, a division of Bausch Health US, LLC | 5 | $100.15 | |
| LEO Pharma Inc. | 4 | $84.12 | |
| MAYNE PHARMA COMMERCIAL LLC | 3 | $69.62 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
1,319
Patients
760
Total drug cost
$41,043
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Triamcinolone Acetonide | Generic | 292 | 179 | $3,327 |
| Ketoconazole | Generic | 153 | 78 | $3,821 |
| Hydrocortisone | Generic | 141 | 95 | $942 |
| Betamethasone Dipropionate | Generic | 139 | 70 | $7,768 |
| Metronidazole | Generic | 117 | 69 | $7,916 |
| Fluocinonide | Generic | 74 | 39 | $6,253 |
| Mometasone Furoate | Generic | 71 | 51 | $1,709 |
| Mupirocin | Generic | 70 | 52 | $719 |
| Valacyclovir (Valacyclovir Hcl) | Brand | 66 | 27 | $1,625 |
| Cephalexin | Generic | 48 | 27 | $396 |